Goldman Sachs Group Inc Cullinan Oncology, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 685,374 shares of CGEM stock, worth $6.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
685,374
Previous 700,552 2.17%
Holding current value
$6.27 Million
Previous $11.7 Million 28.82%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$10.77 - $17.6 $163,467 - $267,132
-15,178 Reduced 2.17%
685,374 $8.35 Million
Q3 2024

Nov 14, 2024
BUY
$16.03 - $20.86 $3.97 Million - $5.17 Million
247,765 Added 54.72%
700,552 $11.7 Million
Q2 2024

Aug 13, 2024
BUY
$15.63 - $29.35 $4.43 Million - $8.32 Million
283,420 Added 167.34%
452,787 $7.9 Million
Q1 2024

May 15, 2024
BUY
$10.17 - $19.02 $417,498 - $780,809
41,052 Added 31.99%
169,367 $2.89 Million
Q4 2023

Feb 13, 2024
BUY
$7.89 - $10.23 $332,989 - $431,746
42,204 Added 49.01%
128,315 $1.31 Million
Q3 2023

May 14, 2024
SELL
$9.05 - $11.72 $381,946 - $494,630
-42,204 Reduced 32.89%
86,111 $779,000
Q3 2023

Nov 14, 2023
SELL
$9.05 - $11.72 $138,609 - $179,503
-15,316 Reduced 15.1%
86,111 $779,000
Q2 2023

May 14, 2024
SELL
$8.8 - $13.4 $689,858 - $1.05 Million
-78,393 Reduced 43.6%
101,427 $1.09 Million
Q2 2023

Aug 14, 2023
SELL
$8.8 - $13.4 $689,858 - $1.05 Million
-78,393 Reduced 43.6%
101,427 $1.09 Million
Q1 2023

May 14, 2024
BUY
$10.2 - $11.91 $121,685 - $142,086
11,930 Added 7.11%
179,820 $1.84 Million
Q1 2023

May 11, 2023
BUY
$10.2 - $11.91 $121,685 - $142,086
11,930 Added 7.11%
179,820 $1.84 Million
Q4 2022

May 14, 2024
SELL
$9.72 - $13.62 $1.54 Million - $2.16 Million
-158,860 Reduced 48.62%
167,890 $1.77 Million
Q4 2022

Feb 13, 2023
SELL
$9.72 - $13.62 $1.54 Million - $2.16 Million
-158,860 Reduced 48.62%
167,890 $1.77 Million
Q3 2022

May 14, 2024
BUY
$11.82 - $15.42 $1.91 Million - $2.49 Million
161,441 Added 97.66%
326,750 $4.19 Million
Q3 2022

Nov 10, 2022
BUY
$11.82 - $15.42 $1.91 Million - $2.49 Million
161,441 Added 97.66%
326,750 $4.19 Million
Q2 2022

May 14, 2024
BUY
$7.31 - $13.55 $270,426 - $501,268
36,994 Added 28.83%
165,309 $2.12 Million
Q2 2022

Aug 15, 2022
BUY
$7.31 - $13.55 $596,919 - $1.11 Million
81,658 Added 97.62%
165,309 $2.12 Million
Q1 2022

May 16, 2022
BUY
$10.47 - $16.75 $34,027 - $54,437
3,250 Added 4.04%
83,651 $876,000
Q4 2021

Feb 14, 2022
SELL
$15.36 - $25.0 $1.18 Million - $1.93 Million
-77,100 Reduced 48.95%
80,401 $1.24 Million
Q3 2021

Nov 10, 2021
BUY
$22.56 - $29.68 $3.55 Million - $4.67 Million
157,501 New
157,501 $3.56 Million

Others Institutions Holding CGEM

# of Institutions
153
Shares Held
67.1M
Call Options Held
41.1K
Put Options Held
112K
View Full List

About Cullinan Oncology, Inc.

CGEM Quotes by TradingView
  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $417M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email